Genspera Inc (GNSZ) 0.7900 $GNSZ GenSpera Contends In

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2015 at 9:06 AM

Genspera Inc (GNSZ) 0.7900 $GNSZ

GenSpera Contends In The Prodrug Space, Reaching Phase 3
Mayer Winkler - at Seeking Alpha - Mon Mar 30, 1:37PM CDT

GenSpera Launches National Investor Relations Program
PR Newswire - Mon Mar 30, 7:10AM CDT
GenSpera Inc. (OTCQB: GNSZ) announced today the selection of PCG Advisory Group (PCG) to launch a comprehensive investor relations initiative for the oncology-focused drug development company. Led by Jeff Ramson, founder and chief executive officer, the PCG team will also be directed by three senior members: Kirin Smith, COO and managing director of investor relations; Jeffrey Hart, managing director of market intelligence; and Sean Leous, CCO. The team will be supported by Carl Mauch, science analyst.

MarketExclusive.com - H.C. Wainwright & Co. Reiterates BUY Rating of GenSpera
ACCESSWIRE - Tue Mar 24, 9:48AM CDT
NEW YORK, NY / ACCESSWIRE / March 24, 2015 / Market Exclusive announces that H.C. Wainwright & Co. continues to rate the shares of GenSpera, Inc. (OTCQB: GNSZ) as Buy with a 12-month price target of $2.00 per share.

GenSpera Inc. - "Why China Matters to GenSpera"
ACCESSWIRE - Mon Mar 23, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / March 23, 2015 / GenSpera Inc. (OTCQB:GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

GenSpera Presents at BIO Asia International Conference
PR Newswire - Tue Mar 17, 7:00AM CDT
GenSpera Inc. (OTCQB: GNSZ) announced today that Craig Dionne, Ph.D., chief executive officer at GenSpera, will present at the 12th Annual BIO Asia International Conference on Tuesday, March 24 at 3:15 p.m. JST at the Grand Hyatt in Tokyo, Japan. The presentation will offer an overview of the latest scientific developments of GenSpera's lead investigational agent mipsagargin and the applicability of its innovative mechanism of action in a broad array of oncology treatments.

Genspera's Mipsagargin Phase 2 Results Impress
Austrolib - at Seeking Alpha - Tue Feb 24, 8:38AM CST

GenSpera Announces Partnership With Global Supplier
PR Newswire - Mon Feb 09, 7:00AM CST
GenSpera, Inc. (OTCQB: GNSZ) today announced a strategic partnership with Phyton Biotech for the manufacture of thapsigargin, which is derived from the thapsia plant and is the key ingredient in the company's investigational agent mipsagargin. Phyton Biotech will offer its Plant Cell Fermentation (PCF®) development expertise to convert the thapsia plant into a preserved, fermentable cell line with a goal of creating a sustainable source of high quality thapsigargin.

GenSpera Presents at BIO CEO & Investor Conference
PR Newswire - Mon Feb 02, 7:00AM CST
GenSpera Inc. (OTCQB: GNSZ) announced today that Craig Dionne, Ph.D., chief executive officer at GenSpera, will present at the 17th Annual BIO CEO & Investor Conference on February 9th at 1 p.m. at the Waldorf Astoria in New York City. The presentation comes as GenSpera continues clinical development of mipsagargin for several tumor types and expands the applicability of its innovative mechanism of action in a broad array of oncology treatments.

GenSpera Announces Positive Phase II Data for Investigational Agent Mipsagargin
PR Newswire - Fri Jan 16, 7:30AM CST
GenSpera Inc. (OTCQB: GNSZ) today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). The results will be presented today (12:00 to 2:00 p.m. PST, Abstract #301) in a poster presentation at the 2015 Gastrointestinal Cancers Symposium in San Francisco, California.

GenSpera Presents at Noble Financial Conference
PR Newswire - Tue Jan 13, 3:15PM CST
GenSpera Inc., (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announced today that Craig A. Dionne, Ph.D., chief executive officer at GenSpera, will present on Monday, January 19, at 12:30 pm EST at the Noble Financial Capital Markets' Eleventh Annual Equity Conference in Sandpiper Bay, Florida.

GenSpera Announces New Digital Channels for Corporate Communications
PR Newswire - Thu Jan 08, 7:00AM CST
GenSpera Inc., (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The company has established official portals on social media channels including: Facebook, Twitter, LinkedIn, Google+, YouTube and The Chairman's Blog.

GenSpera Names JPA Health Communications as Its Agency of Record
PR Newswire - Tue Jan 06, 9:58AM CST
GenSpera, Inc., (OTCQB: GNSZ), a San Antonio based biotech company that develops innovative prodrug therapeutics for the treatment of cancer, announced today that it has named JPA Health Communications as its public relations agency of record.

H.C. Wainwright & Co. Initiates Coverage of GenSpera with a Buy Rating
ACCESSWIRE - Wed Dec 17, 11:05AM CST
New York, NY / ACCESSWIRE / December 17, 2014 / Market Exclusive announces that H.C. Wainwright & Co has initiated coverage with a Buy rating of GenSpera, Inc. (OTCQB: GNSZ) and a 12-month target price of $2.

Genspera, Inc. Featured in TheStockRadio.com Interview
PR Newswire - Tue Dec 02, 7:00AM CST
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing innovative prodrug therapeutics for the treatment of cancer, releases a recent audio interview with TheStockRadio.com. Craig Dionne, PhD, GenSpera's CEO, discusses the company's background and history including the inception and development of the company's lead compound, mipsagargin, at John Hopkins University and its subsequent development by the company. Dr. Dionne also highlights the benefits of mipsagargin over traditional chemotherapeutics, including its limited side effects and more effective tumor killing properties.

Genspera Announces Melanie Thomas, MD, MS, Will Serve Company as Medical Advisor
PR Newswire - Thu Oct 16, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that Melanie Thomas, MD, MS, a recognized worldwide leader in the field of liver cancer, will join the company as Medical Advisor.

GenSpera Announces Completion of Patient Enrollment in the Phase II Clinical Trial of Mipsagargin in Liver Cancer Patients
PR Newswire - Thu Oct 09, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that patient enrollment has been completed in the company's Phase II clinical trial in patients with liver cancer (hepatocellular carcinoma). Formal results of the study are expected to be available during the first quarter of 2015.

GenSpera to Present Lead Drug Candidate Mipsagargin at 2nd Global Life Sciences Conference in Warsaw, Poland
PR Newswire - Tue Sep 30, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces Craig Dionne, PhD, GenSpera's CEO, will be presenting at the upcoming 2nd Global Life Sciences Conference on October 2, 2014, in Warsaw, Poland, on the trading floor of the Warsaw Stock Exchange.

Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
GILD: 101.77 (+0.61), AUXL: 36.47 (-0.06), VVUS: 2.40 (+0.06), LLY: 73.92 (+1.56), ARNA: 4.55 (+0.01), DOW: 48.39 (-0.35), CELG: 117.07 (+1.49), CELGZ: 2.89 (+0.04)

Genspera Wins Summary Judgment in Mhaka Litigation
PR Newswire - Thu Sep 18, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States District Court for the District of Maryland has granted the company's summary judgment with respect to all pending claims asserted against it by Annastasiah Mhaka.

GenSpera Receives Patent on Prodrug Targeted for Prostate Cancer
PR Newswire - Tue Sep 09, 7:20AM CDT
GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs."

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tetragon Declares Dividend Amidst Regulation Challenges

What Keeps Investors on Their Toes Tetragon Financial Group is ringing the dividend bell again—a solid 12 cents a share coming your way. But don't just kick your feet up and watch the cash roll in; there's a tangle of juicy tidbits and regulatory strings attached that make this more than your run-of-the-mill payout announcement. A Look at the Dividend Breakdown For...

UP Fintech Faces Class Action: Key Investor Impacts

UP Fintech's Tumultuous Ride Ever watch a stock tumble and think, "Here we go again?" That's UP Fintech Holding Limited (NASDAQ:TIGR) right now. It's staring down the barrel of a securities fraud class action lawsuit, and trust me, it's messier than yesterday's lunch special. The stock's already gone through the wringer, dropping a hefty 25.34% after some nasty news from...

TEN Holdings' Q3: Cost Cuts Fuel Revenue Ambitions

TEN Holdings Eyes the Future While Cleaning House If there’s one thing that catches the eye about TEN Holdings' Q3 2026 results, it’s the laser-focused cleanup of their balance sheet. They’ve slashed liabilities by 74%, up from $7.7 million at the arse end of last year to just over $2 million now. They did that by making some hard moves, hacking away at operating...

West Virginia Water Gains: Central Grove Upgrade Begins

Kickoff at Central Grove: What’s Brewing? Ever wander through Kearneysville, W.Va., and wonder what’s going on with that bustling crew near Goldenrod Drive? The folks at West Virginia American Water have kicked off groundwork for the much-anticipated Central Grove Water Treatment Plant. This, comrades, isn’t just some shiny new shed we’re talking about. Oh no,...

Adding Fireplaces: Home Comfort or Construction Headache?

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

An Extra Helping of Community Spirit Rutter Mills is back on the scene again this Thanksgiving, slinging out a thousand turkeys to show their appreciation for the community they’ve called home since 1959. This initiative is the second iteration of their Turkey Drop, an event that's set to become a cherished tradition for years to come. Last year's event only teased the...

Milton Hershey School's New Project: Founders Grove Launches

Breaking New Ground with Founders Grove It’s not every day a community gets a new lease on life through bricks and mortar, but Milton Hershey School (MHS) just did exactly that. They've broken ground on Founders Grove, a piece of the Hershey West End development puzzle that reflects both history and future potential. This isn’t just another housing project—this...

Detroit Hosts Groundbreaking AquaHacking Challenge

Shaking Up the Water Scene in Detroit Forget Wall Street for a moment—there's a new kind of trading floor where the stakes are nothing less than the health of our waterways. Yesterday, Detroit saw the Great Lakes and St. Lawrence Binational AquaHacking Challenge 2026 wrap up with a bang, having gathered 12 fiery teams on a mission to tackle urgent water issues head-on....

AXON Revenue Forecast Cut Spurs Legal Investigation

Axon's Revenue Forecast Takes a Hit Listen up, folks. Axon Enterprise, Inc. (NASDAQ: AXON) has stirred the pot, cutting their 2026 revenue forecast faster than you can say "counter-drone deployment." Back in August, they were riding high on their second-quarter call, raising their growth forecast to a cheerful 32%-34%. Fast forward to November, and it's been slashed to...

Pigeon Unveils Green Innovations at CIIE 2026

An International Celebration: Cultural Connections at CIIE Babies have a way of bringing the world together. Every culture has its own quirks and traditions, but the love for a newborn is common ground. Pigeon gets that, and they're putting it on full display at the China International Import Expo (CIIE) in Shanghai. It's their fourth run at this rodeo, and they’re not...